ATE235918T1 - Hydroxamsäurederivat und antitumormittel enthaltende pharmazeutische zusammensetzung mit verbesserter antitumor-aktivität und/oder verringerten nebenwirkungen - Google Patents

Hydroxamsäurederivat und antitumormittel enthaltende pharmazeutische zusammensetzung mit verbesserter antitumor-aktivität und/oder verringerten nebenwirkungen

Info

Publication number
ATE235918T1
ATE235918T1 AT98925873T AT98925873T ATE235918T1 AT E235918 T1 ATE235918 T1 AT E235918T1 AT 98925873 T AT98925873 T AT 98925873T AT 98925873 T AT98925873 T AT 98925873T AT E235918 T1 ATE235918 T1 AT E235918T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
composition containing
side effects
acid derivative
antitumor activity
Prior art date
Application number
AT98925873T
Other languages
English (en)
Inventor
Balazs Suemegi
Original Assignee
N Gene Res Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N Gene Res Lab Inc filed Critical N Gene Res Lab Inc
Application granted granted Critical
Publication of ATE235918T1 publication Critical patent/ATE235918T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98925873T 1997-06-23 1998-06-22 Hydroxamsäurederivat und antitumormittel enthaltende pharmazeutische zusammensetzung mit verbesserter antitumor-aktivität und/oder verringerten nebenwirkungen ATE235918T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9701081A HU9701081D0 (en) 1997-06-23 1997-06-23 Pharmaceutical composition of antitumoral activity
PCT/IB1998/000961 WO1998058676A1 (en) 1997-06-23 1998-06-22 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxamic acid derivative

Publications (1)

Publication Number Publication Date
ATE235918T1 true ATE235918T1 (de) 2003-04-15

Family

ID=89995266

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98925873T ATE235918T1 (de) 1997-06-23 1998-06-22 Hydroxamsäurederivat und antitumormittel enthaltende pharmazeutische zusammensetzung mit verbesserter antitumor-aktivität und/oder verringerten nebenwirkungen

Country Status (25)

Country Link
US (4) US6440998B1 (de)
EP (1) EP0993304B1 (de)
JP (1) JP2002508762A (de)
KR (1) KR20010020496A (de)
CN (1) CN1127984C (de)
AT (1) ATE235918T1 (de)
AU (1) AU735922B2 (de)
BR (1) BR9810312A (de)
CA (1) CA2294913C (de)
CZ (1) CZ298468B6 (de)
DE (1) DE69812949T2 (de)
DK (1) DK0993304T3 (de)
ES (1) ES2195344T3 (de)
HK (1) HK1029941A1 (de)
HU (1) HU9701081D0 (de)
IL (1) IL133508A (de)
NO (1) NO322206B1 (de)
NZ (1) NZ502039A (de)
PL (1) PL191718B1 (de)
PT (1) PT993304E (de)
RU (2) RU2214238C2 (de)
SK (1) SK282877B6 (de)
TR (1) TR199903214T2 (de)
UA (1) UA64757C2 (de)
WO (1) WO1998058676A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884424B2 (en) * 1995-12-22 2005-04-26 N-Gene Research Laboratories Inc. Method for treating the pathological lesions of the skin that develop by ultraviolet radiation of the sunlight
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
SI2368553T1 (sl) 2003-04-08 2015-05-29 Progenics Pharmaceuticals, Inc. Farmacevtske formulacije, vsebujoče metilnatrekson
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
US7763601B2 (en) * 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
US20080108602A1 (en) * 2006-11-02 2008-05-08 N-Gene Research Laboratories, Inc. Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
EP3064503A1 (de) * 2007-03-29 2016-09-07 Progenics Pharmaceuticals, Inc. Antagonisten der peripheren opioidrezeptoren und ihre verwendung
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
JP2011502112A (ja) * 2007-10-30 2011-01-20 トロフォ 抗ガン治療の副作用を治療するための新規組成物
WO2009074835A1 (en) * 2007-12-10 2009-06-18 N-Gene Research Laboratories Inc. Dose reduction of a cannabinoid cb1 receptor antagonist in the treatment of overweight or obesity
CA2713568C (en) * 2008-02-06 2016-09-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
WO2009117669A2 (en) 2008-03-21 2009-09-24 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
ITMI20110791A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
ITMI20110792A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100445A2 (en) * 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
RU2522548C2 (ru) * 2012-09-26 2014-07-20 Федеральное государственное бюджетное учреждение науки Институт кристаллографии им. А.В. Шубникова Российской академии наук (ИК РАН) Ингибитор уридинфосфорилаз
US9938279B2 (en) * 2013-04-09 2018-04-10 Energenesis Biomedical Co., Ltd Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK)
CN108703970A (zh) * 2013-09-18 2018-10-26 华安医学股份有限公司 一种活化ampk的化合物及其用途
RU2679136C1 (ru) * 2018-03-13 2019-02-06 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр "Красноярский научный центр Сибирского отделения Российской академии наук" (ФИЦ КНЦ СО РАН, КНЦ СО РАН) Способ получения препарата на основе взаимодействия цис-диамин(циклобутан-1,1-дикарбоксилат-о,о')платины(ii) с арабиногалактаном
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308399A (en) * 1977-08-30 1981-12-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HUT54347A (en) * 1989-01-10 1991-02-28 Chinoin Gyogyszer Es Vegyeszet Improved process for producing amidoximes
RO118000B1 (ro) * 1993-03-31 2002-12-30 Merck & Co Inc Metoda pentru tratamentul sida, prevenirea si tratamentul infectiei cu hiv sau inhibarea proteazei hiv si compozitie farmaceutica pentru aplicarea metodei
CA2128044C (en) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
HU9502843D0 (en) * 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells

Also Published As

Publication number Publication date
RU2214238C2 (ru) 2003-10-20
RU2254129C2 (ru) 2005-06-20
SK176499A3 (en) 2000-09-12
US20030069270A1 (en) 2003-04-10
US6656955B2 (en) 2003-12-02
EP0993304B1 (de) 2003-04-02
JP2002508762A (ja) 2002-03-19
CZ462599A3 (cs) 2000-05-17
CN1127984C (zh) 2003-11-19
US6720337B2 (en) 2004-04-13
US20030050345A1 (en) 2003-03-13
DE69812949D1 (de) 2003-05-08
DE69812949T2 (de) 2004-02-05
AU7783798A (en) 1999-01-04
US6440998B1 (en) 2002-08-27
NO996349D0 (no) 1999-12-20
NO996349L (no) 2000-02-23
CA2294913C (en) 2008-12-16
EP0993304A1 (de) 2000-04-19
CA2294913A1 (en) 1998-12-30
PT993304E (pt) 2003-08-29
US20020147213A1 (en) 2002-10-10
CZ298468B6 (cs) 2007-10-10
PL191718B1 (pl) 2006-06-30
NO322206B1 (no) 2006-08-28
CN1263471A (zh) 2000-08-16
WO1998058676A1 (en) 1998-12-30
US6838469B2 (en) 2005-01-04
HK1029941A1 (en) 2001-04-20
ES2195344T3 (es) 2003-12-01
AU735922B2 (en) 2001-07-19
DK0993304T3 (da) 2003-07-28
TR199903214T2 (xx) 2000-12-21
NZ502039A (en) 2002-03-28
BR9810312A (pt) 2000-09-19
KR20010020496A (ko) 2001-03-15
HU9701081D0 (en) 1997-08-28
SK282877B6 (sk) 2003-01-09
UA64757C2 (uk) 2004-03-15
IL133508A (en) 2005-11-20
PL337719A1 (en) 2000-08-28
IL133508A0 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
ATE235918T1 (de) Hydroxamsäurederivat und antitumormittel enthaltende pharmazeutische zusammensetzung mit verbesserter antitumor-aktivität und/oder verringerten nebenwirkungen
FR2757522B1 (fr) Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
DK1030670T3 (da) Anvendelse af vitamin D-derivater til forstærkning af virkningen af cytotoksiske midler
CA2171275A1 (en) Stilbene derivatives and pharmaceutical compositions containing them
FR2757521B1 (fr) Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
TR199900674T2 (xx) Kinazolin t�revleri ve bunlar� i�eren farmas�tik bile�imler.
CA2295035A1 (en) Pharmaceutical formulations containing voriconazole
FI962735A0 (fi) 2-hydroksi-5-fenylatsobensoehapon johdannaisten käyttö paksusuolen syövän kemialliseen ehkäisyyn ja kemoterapeuttisena aineena
WO2000045800A3 (en) Immunosurpressive effects of pteridine derivatives
HU229443B1 (en) Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use
TR199900336T2 (xx) EAA antagonistleri olarak tetrahidrokinolin t�revleri.
EP0620004A4 (de) Medizinische zusammensetzung.
JP2000159790A5 (de)
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
BG104436A (en) The administration of macrolides for the treatment of cancer and macular degeneration
TR200002766T2 (tr) 3',3'-N-Bis-ikameli makrolit LHRH Antagonistleri
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
TR200102236T2 (tr) Kolesterol-düşürme amilinin kullanımı.
MA26447A1 (fr) Analogues peptidiques de la lh-rh, leurs utilisations et compositions pharmaceutiques en contenant
CA2182812A1 (en) Pharmaceutical composition for systemic transdermal administration containing the active agent morphine-6-glucuronide
FR2751967B1 (fr) Agents antipaludeens et antibabesioses et compositions pharmaceutiques les contenant
GB0122257D0 (en) Simplified sarcodictyin derivatives
TR200102196T2 (tr) Mono-asiloksi aralkil nöromuskular relaksanları.
EP0880966A4 (de) Thiamindisulfide und diese als wirkstoff enthaltende medikamente

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0993304

Country of ref document: EP

REN Ceased due to non-payment of the annual fee